Testing an Arts-based Program to Reduce Nurse Stigma Towards Perinatal Substance Use

Feasibility of an Art-based Intervention to Address Clinician Stigma and Improve Care for Neonatal Opioid Withdrawal Syndrome

The goal of this pilot clinical trial is to evaluate the feasibility and limited effectiveness of a digital, arts-based educational intervention addressing nurse stigma towards perinatal substance use. The main questions it aims to answer are:

• What is the the feasibility of delivering the training through an asynchronous, web-based platform?
• What is the limited effectiveness of the program on nurse stigma towards perinatal substance use?

Participants will access and complete the training, including completion of a perinatal substance use stigma scale at baseline, immediately post, and 1-2 months month later. Participants will also be invited to participate in an interview.

Researchers will compare the intervention and control groups to see if the training reduces nurse stigma towards perinatal substance use.

Study Overview

• Status: Completed
• Conditions: Nurse's Role; Stigma, Social; Implicit Bias
• Intervention / Treatment: Other: ArtSpective

• Study Type: Interventional
• Enrollment (Actual): 99
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Minnesota
    • Saint Cloud, Minnesota, United States, 56303
      • St. Cloud Hospital
  • Ohio
    • Toledo, Ohio, United States, 43606
      • ProMedica Toledo Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age 18 years or older
• Licensed as a registered nurse
• Works at least part time
• Works on a labor, postpartum, nursery, neonatal intensive care, or pediatric unit in one of the participating hospitals

Exclusion Criteria:

• Works as per diem or agency nurse
• Not employed by a participating hospital
• Not a perinatal/pediatric nurse

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Site 1; Participants from the hospital randomized to the experimental group will be first to receive an invitation to complete the web-based educational program. The program will be open for one month. Thirty days after a participant completes the program, they will be sent a link to a follow up survey (web-based). At 60 days, participants who completed the program and the first follow up survey will be randomized to complete a second follow up survey or participate in a 1:1 interview.	Other: ArtSpective; ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.
Other: Site 2; Participants from the hospital randomized to the control setting will receive an invitation to complete a survey that collects baseline data for the outcome (stigma toward perinatal substance use) and demographic information. After thirty days, participants will be invited to complete the web-based educational program. Thirty days after completion, they will receive a link to a web-based follow up survey.	Other: ArtSpective; ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Nurse Stigma Toward Perinatal Substance Use	Negative or stigmatizing attitudes and/or beliefs registered nurses have towards perinatal substance use; measured using the Modified Attitudes About Drug Use in Pregnancy Scale. Total scores range between 1 and 5, with scores closer to 1 associated with a more positive outcome.	Baseline (Phase 1a); immediately post intervention (Site 1) or 7-30 days post baseline (Site 2) (Phase 1b); immediately post (Site 2) or 30 days post intervention (Site 1) (Phase 2); 30 days post (Site 2) or 60 days post intervention (Site 1) (Phase 3)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptability	The level of satisfaction participants have towards the intervention; measured using an adapted version of the Abbreviated Acceptability Rating Profile. Total scores range from 1 to 5 with scores closer to 5 representing a more positive outcome.	immediately post intervention (Site 1= Phase 1b; Site 2 = Phase 2)

Collaborators and Investigators

• Sponsor: University of Michigan
• Collaborators: National Institute on Drug Abuse (NIDA)

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2024
• Primary Completion (Actual): November 30, 2024
• Study Completion (Actual): November 30, 2024

Study Registration Dates

• First Submitted: May 7, 2024
• First Submitted That Met QC Criteria: May 10, 2024
• First Posted (Actual): May 13, 2024

Study Record Updates

• Last Update Posted (Actual): March 11, 2026
• Last Update Submitted That Met QC Criteria: March 9, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavior; Social Behavior; Prejudice; Social Stigma; Bias, Implicit
• Other Study ID Numbers: HUM00248695; R21DA055067 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: De-identified data may be shared upon request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No